{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T21:37:53Z","timestamp":1793828273634,"version":"4.6.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T00:00:00Z","timestamp":1612828800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T00:00:00Z","timestamp":1612828800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Key R&D Program of China","award":["2018YFC1314702"],"award-info":[{"award-number":["2018YFC1314702"]}]},{"name":"Shanghai Municipal Science and Technology Major Project","award":["No.2018SHZDZX01"],"award-info":[{"award-number":["No.2018SHZDZX01"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Observational studies suggest that the use of antihypertensive medications (AHMs) is associated with a reduced risk of Alzheimer\u2019s disease (AD); however, these findings may be biased by confounding and reverse causality. We aimed to explore the effects of blood pressure (BP) and lowering systolic BP (SBP) via the protein targets of different AHMs on AD through a two-sample Mendelian randomization (MR) approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Genetic proxies from genome-wide association studies of BP traits and BP-lowering variants in genes encoding AHM targets were extracted. Estimates were calculated by inverse-variance weighted method as the main model. MR Egger regression and leave-one-out analysis were performed to identify potential violations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      There was limited evidence that genetically predicted SBP\/diastolic BP level affected AD risk based on 400\/398 single nucleotide polymorphisms (SNPs), respectively (all\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&gt;\u20090.05). Suitable genetic variants for \u03b2-blockers (1 SNP), angiotensin receptor blockers (1 SNP), calcium channel blockers (CCBs, 45 SNPs), and thiazide diuretics (5 SNPs) were identified. Genetic proxies for CCB [odds ratio (OR)\u2009=\u20090.959, 95% confidence interval (CI)\u2009=\u20090.941\u20130.977,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20093.92\u2009\u00d7\u200910\n                      <jats:sup>\u22126<\/jats:sup>\n                      ] and overall use of AHMs (OR\u2009=\u20090.961, 95% CI\u2009=\u20090.944\u20130.978,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20095.74\u2009\u00d7\u200910\n                      <jats:sup>\u22126<\/jats:sup>\n                      , SNPs\u2009=\u200952) were associated with a lower risk of AD. No notable heterogeneity and directional pleiotropy were identified (all\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&gt;\u20090.05). Additional analyses partly support these results. No single SNP was driving the observed effects.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This MR analysis found evidence that genetically determined lowering BP was associated with a lower risk of AD and CCB was identified as a promising strategy for AD prevention.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13195-021-00782-y","type":"journal-article","created":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T13:13:51Z","timestamp":1612876431000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Genetically determined blood pressure, antihypertensive medications, and risk of Alzheimer\u2019s disease: a Mendelian randomization study"],"prefix":"10.1186","volume":"13","author":[{"given":"Ya-Nan","family":"Ou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Xiang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Ning","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Hui","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Dong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7686-0547","authenticated-orcid":false,"given":"Jin-Tai","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,9]]},"reference":[{"key":"782_CR1","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1016\/S0140-6736(17)31363-6","volume":"390","author":"G Livingston","year":"2017","unstructured":"Livingston G, Sommerlad A, Orgeta V, Costafreda SG, Huntley J, Ames D, et al. Dementia prevention, intervention, and care. Lancet. 2017;390:2673\u2013734.","journal-title":"Lancet"},{"key":"782_CR2","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/S1474-4422(05)70141-1","volume":"4","author":"C Qiu","year":"2005","unstructured":"Qiu C, Winblad B, Fratiglioni L. The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol. 2005;4:487\u201399.","journal-title":"Lancet Neurol."},{"key":"782_CR3","first-page":"1299","volume":"86","author":"W Xu","year":"2015","unstructured":"Xu W, Tan L, Wang HF, et al. Meta-analysis of modifiable risk factors for Alzheimer\u2019s disease. J Neurol Neurosurg Psychiatry. 2015;86:1299\u2013306.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"782_CR4","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S1474-4422(19)30393-X","volume":"19","author":"J Ding","year":"2020","unstructured":"Ding J, Davis-Plourde KL, Sedaghat S, Tully PJ, Wang W, Phillips C, et al. Antihypertensive medications and risk for incident dementia and Alzheimer\u2019s disease: a meta-analysis of individual participant data from prospective cohort studies. Lancet Neurol. 2020;19:61\u201370.","journal-title":"Lancet Neurol."},{"key":"782_CR5","doi-asserted-by":"publisher","first-page":"e1002660","DOI":"10.1371\/journal.pmed.1002660","volume":"15","author":"B Lawlor","year":"2018","unstructured":"Lawlor B, Segurado R, Kennelly S, Olde Rikkert MGM, Howard R, Pasquier F, et al. Nilvadipine in mild to moderate Alzheimer disease: a randomised controlled trial. Plos Med. 2018;15:e1002660.","journal-title":"Plos Med"},{"key":"782_CR6","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1093\/ije\/dyx207","volume":"46","author":"VM Walker","year":"2017","unstructured":"Walker VM, Davey Smith G, Davies NM, Martin RM. Mendelian randomization: a novel approach for the prediction of adverse drug events and drug repurposing opportunities. Int J Epidemiol. 2017;46:2078\u201389.","journal-title":"Int J Epidemiol"},{"key":"782_CR7","doi-asserted-by":"publisher","first-page":"k601","DOI":"10.1136\/bmj.k601","volume":"362","author":"NM Davies","year":"2018","unstructured":"Davies NM, Holmes MV, Davey SG. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. BMJ. 2018;362:k601.","journal-title":"BMJ."},{"key":"782_CR8","doi-asserted-by":"publisher","first-page":"e1001841","DOI":"10.1371\/journal.pmed.1001841","volume":"12","author":"SD Ostergaard","year":"2015","unstructured":"Ostergaard SD, Mukherjee S, Sharp SJ, Proitsi P, Lotta LA, Day F, et al. Associations between potentially modifiable risk factors and Alzheimer disease: a Mendelian randomization study. PLoS Med. 2015;12:e1001841 discussion e41.","journal-title":"PLoS Med"},{"key":"782_CR9","doi-asserted-by":"publisher","first-page":"j5375","DOI":"10.1136\/bmj.j5375","volume":"359","author":"SC Larsson","year":"2017","unstructured":"Larsson SC, Traylor M, Malik R, Dichgans M, Burgess S, Markus HS, et al. Modifiable pathways in Alzheimer\u2019s disease: Mendelian randomisation analysis. BMJ. 2017;359:j5375.","journal-title":"BMJ."},{"key":"782_CR10","doi-asserted-by":"crossref","unstructured":"Andrews SJ, Fulton-Howard B, O'Reilly P, Marcora E, Goate AM. Causal associations between modifiable risk factors and the Alzheimer\u2019s phenome. Ann Neurol. 2020;89:54\u201365.","DOI":"10.1002\/ana.25918"},{"key":"782_CR11","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/ana.25642","volume":"87","author":"DM Williams","year":"2020","unstructured":"Williams DM, Finan C, Schmidt AF, Burgess S, Hingorani AD. Lipid lowering and Alzheimer disease risk: a mendelian randomization study. Ann Neurol. 2020;87:30\u20139.","journal-title":"Ann Neurol"},{"key":"782_CR12","doi-asserted-by":"crossref","unstructured":"Walker VM, Kehoe PG, Martin RM, Davies NM. Repurposing antihypertensive drugs for the prevention of Alzheimer\u2019s disease: a Mendelian randomization study. Int J Epidemiol. 2019;49:1132\u201340.","DOI":"10.1093\/ije\/dyz155"},{"key":"782_CR13","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1038\/s41588-018-0205-x","volume":"50","author":"E Evangelou","year":"2018","unstructured":"Evangelou E, Warren HR, Mosen-Ansorena D, Mifsud B, Pazoki R, Gao H, et al. Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits. Nat Genet. 2018;50:1412\u201325.","journal-title":"Nat Genet"},{"key":"782_CR14","first-page":"CD001841","volume":"4","author":"JM Wright","year":"2018","unstructured":"Wright JM, Musini VM, Gill R. First-line drugs for hypertension. Cochrane Database Syst Rev. 2018;4:CD001841.","journal-title":"Cochrane Database Syst Rev"},{"key":"782_CR15","doi-asserted-by":"publisher","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","volume":"46","author":"DS Wishart","year":"2018","unstructured":"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018;46:D1074\u2013D82.","journal-title":"Nucleic Acids Res"},{"key":"782_CR16","doi-asserted-by":"crossref","unstructured":"Fishilevich S, Nudel R, Rappaport N, Hadar R, Plaschkes I, Iny Stein T, et al. GeneHancer: genome-wide integration of enhancers and target genes in GeneCards. Database (Oxford). 2017;2017:bax028.","DOI":"10.1093\/database\/bax028"},{"key":"782_CR17","doi-asserted-by":"publisher","first-page":"3957","DOI":"10.1038\/s41467-018-06467-9","volume":"9","author":"C Nowak","year":"2018","unstructured":"Nowak C, Arnlov J. A Mendelian randomization study of the effects of blood lipids on breast cancer risk. Nat Commun. 2018;9:3957.","journal-title":"Nat Commun"},{"key":"782_CR18","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1001\/jamacardio.2018.1470","volume":"3","author":"S Burgess","year":"2018","unstructured":"Burgess S, Ference BA, Staley JR, Freitag DF, Mason AM, Nielsen SF, et al. Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a Mendelian randomization analysis. JAMA Cardiol. 2018;3:619\u201327.","journal-title":"JAMA Cardiol"},{"key":"782_CR19","doi-asserted-by":"crossref","unstructured":"Georgakis MK, Gill D, Webb AJS, Evangelou E. Genetically determined blood pressure, antihypertensive drug classes, and risk of stroke subtypes. Neurology. 2020;95:e353\u2013e361.","DOI":"10.1212\/WNL.0000000000009814"},{"key":"782_CR20","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/s41588-019-0358-2","volume":"51","author":"BW Kunkle","year":"2019","unstructured":"Kunkle BW, Grenier-Boley B, Sims R, Bis JC, Damotte V, Naj AC, et al. Genetic meta-analysis of diagnosed Alzheimer\u2019s disease identifies new risk loci and implicates A\u03b2, tau, immunity and lipid processing. Nat Genet. 2019;51:414\u201330.","journal-title":"Nat Genet"},{"key":"782_CR21","doi-asserted-by":"publisher","first-page":"R89","DOI":"10.1093\/hmg\/ddu328","volume":"23","author":"G Davey Smith","year":"2014","unstructured":"Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. Hum Mol Genet. 2014;23:R89\u201398.","journal-title":"Hum Mol Genet"},{"key":"782_CR22","doi-asserted-by":"publisher","first-page":"e82","DOI":"10.1002\/cphg.82","volume":"101","author":"D Rasooly","year":"2019","unstructured":"Rasooly D, Patel CJ. Conducting a reproducible Mendelian randomization analysis using the R analytic statistical environment. Curr Protoc Human Genet. 2019;101:e82.","journal-title":"Curr Protoc Human Genet"},{"key":"782_CR23","doi-asserted-by":"publisher","first-page":"e1001462","DOI":"10.1371\/journal.pmed.1001462","volume":"10","author":"I Pichler","year":"2013","unstructured":"Pichler I, Del Greco MF, Gogele M, Lill CM, Bertram L, Do CB, et al. Serum iron levels and the risk of Parkinson disease: a Mendelian randomization study. Plos Med. 2013;10:e1001462.","journal-title":"Plos Med"},{"key":"782_CR24","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1093\/ije\/dyv080","volume":"44","author":"J Bowden","year":"2015","unstructured":"Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol. 2015;44:512\u201325.","journal-title":"Int J Epidemiol"},{"key":"782_CR25","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s10654-017-0255-x","volume":"32","author":"S Burgess","year":"2017","unstructured":"Burgess S, Thompson SG. Interpreting findings from Mendelian randomization using the MR-Egger method. Eur J Epidemiol. 2017;32:377\u201389.","journal-title":"Eur J Epidemiol"},{"key":"782_CR26","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1093\/ije\/dyr036","volume":"40","author":"S Burgess","year":"2011","unstructured":"Burgess S, Thompson SG, Collaboration CCG. Avoiding bias from weak instruments in Mendelian randomization studies. Int J Epidemiol. 2011;40:755\u201364.","journal-title":"Int J Epidemiol"},{"key":"782_CR27","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13195-017-0262-x","volume":"9","author":"JM Gabin","year":"2017","unstructured":"Gabin JM, Tambs K, Saltvedt I, Sund E, Holmen J. Association between blood pressure and Alzheimer disease measured up to 27 years prior to diagnosis: the HUNT Study. Alzheimers Res Ther. 2017;9:37.","journal-title":"Alzheimers Res Ther"},{"key":"782_CR28","doi-asserted-by":"crossref","unstructured":"Ou YN, Tan CC, Shen XN, Xu W, Hou XH, Dong Q, et al. Blood pressure and risks of cognitive impairment and dementia: a systematic review and meta-analysis of 209 prospective studies. Hypertension. 2020;76:217\u201325.","DOI":"10.1161\/HYPERTENSIONAHA.120.14993"},{"key":"782_CR29","doi-asserted-by":"crossref","unstructured":"Richardson TG, Harrison S, Hemani G, Davey SG. An atlas of polygenic risk score associations to highlight putative causal relationships across the human phenome. eLife. 2019;8:e43657.","DOI":"10.7554\/eLife.43657"},{"key":"782_CR30","doi-asserted-by":"crossref","unstructured":"Korologou-Linden R, Howe LD, Millard LAC, Ben-Shlomo Y, Williams DM, Davey Smith G, et al. The causes and consequences of Alzheimer\u2019s disease: phenome-wide evidence from Mendelian randomization. medRxiv. 2019.12.18.19013847.","DOI":"10.1101\/2019.12.18.19013847"},{"key":"782_CR31","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/S1474-4422(19)30228-5","volume":"18","author":"CA Lane","year":"2019","unstructured":"Lane CA, Barnes J, Nicholas JM, Sudre CH, Cash DM, Parker TD, et al. Associations between blood pressure across adulthood and late-life brain structure and pathology in the neuroscience substudy of the 1946 British birth cohort (Insight 46): an epidemiological study. Lancet Neurol. 2019;18:942\u201352.","journal-title":"Lancet Neurol"},{"key":"782_CR32","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1002\/ana.25228","volume":"83","author":"KB Rajan","year":"2018","unstructured":"Rajan KB, Barnes LL, Wilson RS, Weuve J, McAninch EA, Evans DA. Blood pressure and risk of incident Alzheimer\u2019s disease dementia by antihypertensive medications and APOE epsilon4 allele. Ann Neurol. 2018;83:935\u201344.","journal-title":"Ann Neurol"},{"key":"782_CR33","doi-asserted-by":"publisher","first-page":"317","DOI":"10.3233\/JAD-190402","volume":"71","author":"EEF Kleipool","year":"2019","unstructured":"Kleipool EEF, Trappenburg MC, Rhodius-Meester HFM, Lemstra AW, van der Flier WM, Peters MJL, et al. Orthostatic hypotension: an important risk factor for clinical progression to mild cognitive impairment or dementia. The Amsterdam Dementia Cohort. J Alzheimer\u2019s Dis. 2019;71:317\u201325.","journal-title":"J Alzheimer\u2019s Dis"},{"key":"782_CR34","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1001\/jama.2018.21442","volume":"321","author":"JD Williamson","year":"2019","unstructured":"Group SMIftSR, Williamson JD, Pajewski NM, Auchus AP, Bryan RN, Chelune G, et al. Effect of intensive vs standard blood pressure control on probable dementia: a randomized clinical trial. JAMA. 2019;321:553\u201361.","journal-title":"JAMA"},{"key":"782_CR35","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1161\/HYPERTENSIONAHA.119.12892","volume":"74","author":"DLK de Jong","year":"2019","unstructured":"de Jong DLK, de Heus RAA, Rijpma A, Donders R, Olde Rikkert MGM, Gunther M, et al. Effects of nilvadipine on cerebral blood flow in patients with Alzheimer disease. Hypertension. 2019;74:413\u201320.","journal-title":"Hypertension."},{"key":"782_CR36","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1080\/14737175.2020.1708195","volume":"20","author":"T Lebouvier","year":"2020","unstructured":"Lebouvier T, Chen Y, Duriez P, Pasquier F, Bordet R. Antihypertensive agents in Alzheimer\u2019s disease: beyond vascular protection. Expert Rev Neurother. 2020;20:175\u201387.","journal-title":"Expert Rev Neurother"},{"key":"782_CR37","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1126\/science.318.5849.384","volume":"318","author":"JM","year":"2007","unstructured":"JM. Fresh evidence points to an old suspect: calcium. Science. 2007;318:384\u20135.","journal-title":"Science"},{"key":"782_CR38","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nrcardio.2017.78","volume":"14","author":"MV Holmes","year":"2017","unstructured":"Holmes MV, Ala-Korpela M, Smith GD. Mendelian randomization in cardiometabolic disease: challenges in evaluating causality. Nat Rev Cardiol. 2017;14:577\u201390.","journal-title":"Nat Rev Cardiol"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-021-00782-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13195-021-00782-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-021-00782-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T13:15:57Z","timestamp":1612876557000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-021-00782-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,9]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["782"],"URL":"https:\/\/doi.org\/10.1186\/s13195-021-00782-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-125105\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-125105\/v2","asserted-by":"object"}]},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,9]]},"assertion":[{"value":"29 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Written informed consent was obtained from study participants or caregivers. Study protocols for all populations were approved by the appropriate Institutional review boards.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"41"}}